Blood pressure medications and erectile dysfunction are frequently discussed together, but the relationship is more complicated than a simple side effect. Hypertension itself can damage the blood vessels required for an erection, while some antihypertensive drugs may affect sexual function more than others. Recent reviews also challenge older assumptions about entire medication classes. For men who notice a change after starting treatment, the useful question is not whether blood pressure should be treated—it should—but how the underlying disease, the medication, and other risk factors may each contribute.
Why Hypertension Can Affect Erections
An erection is a vascular event. Sexual stimulation triggers nitric oxide release in penile tissue, relaxing smooth muscle and allowing the arteries to deliver more blood. The expanding erectile tissue then compresses venous outflow, helping maintain rigidity. This sequence depends on healthy endothelium, responsive smooth muscle, intact nerves, and adequate blood flow.
Chronic hypertension can disrupt several parts of this system. Persistently elevated pressure promotes endothelial dysfunction, arterial stiffness, oxidative stress, and structural changes in small blood vessels. Because penile arteries are narrower than coronary or carotid arteries, impaired vascular function may become noticeable there relatively early. Erectile dysfunction can therefore reflect the vascular effects of hypertension even before medication is considered.
Hypertension and erectile dysfunction also share common drivers: age, diabetes, abdominal obesity, smoking, sleep apnea, low physical activity, kidney disease, and dyslipidemia. Anxiety about cardiovascular health or sexual performance may add a psychological component. In practice, a new erectile problem often has more than one cause.
A 2023 Mendelian randomization analysis found that genetically predicted hypertension was associated with erectile dysfunction, while finding little evidence that genetic proxies for several blood-pressure-lowering drug classes increased risk [1]. Mendelian randomization cannot reproduce a clinical trial, but the result reinforces an important point: untreated vascular disease is itself a plausible contributor.
Blood Pressure Medications and Erectile Dysfunction by Drug Class
The best available evidence does not support treating all antihypertensive drugs as equivalent. A 2022 network meta-analysis of 25 randomized studies involving 7,784 participants found no statistically significant differences in erectile function among the major classes overall [2]. However, many included studies had a concerning or high risk of bias, so a neutral pooled result does not mean that no individual ever experiences a medication-related effect.
Beta-blockers. Older, non-vasodilating beta-blockers have the strongest historical association with sexual side effects. Proposed mechanisms include reduced sympathetic activity, lower penile blood flow, fatigue, and effects on central arousal. Yet results vary by agent. Nebivolol promotes nitric-oxide-mediated vasodilation and may have a more favorable sexual profile than older drugs such as metoprolol or atenolol. In the 2022 analysis, nebivolol performed better than non-vasodilating beta-blockers, although it was not significantly better than placebo [2].
Thiazide diuretics. Thiazides have also been blamed for erectile dysfunction, partly on the basis of older trials. More recent reviews find the signal less consistent. These medications can be highly effective for preventing stroke and other cardiovascular events, and an erectile symptom alone does not establish causation.
ACE inhibitors and angiotensin receptor blockers. ACE inhibitors are generally considered neutral with respect to erectile function. Angiotensin receptor blockers, or ARBs, may theoretically support vascular relaxation by limiting angiotensin II activity, but clinical evidence for a meaningful improvement in erections remains mixed. Some studies report better sexual activity without a clear improvement in validated erectile-function scores.
Calcium channel blockers. These are usually regarded as neutral. They lower blood pressure through arterial smooth-muscle relaxation without consistently interfering with the hormonal or neural pathways involved in sexual response.
Centrally acting agents. Older drugs such as clonidine and methyldopa have a more established association with sexual dysfunction, although they are used less commonly for routine hypertension management today.
What Recent Research Changes—and What It Does Not
A 2025 review by Corona and colleagues combined a broad evidence review with a focused systematic assessment of beta-blockers [3]. The authors concluded that centrally acting drugs have the clearest negative signal; calcium channel blockers are broadly neutral; ACE inhibitors and ARBs are neutral or potentially favorable; and beta-blockers remain the group most often associated with erectile dysfunction. They also emphasized heterogeneity within the beta-blocker class, with nebivolol appearing more favorable.
That conclusion is more nuanced than the common claim that “blood pressure pills cause ED.” Randomized studies have not consistently demonstrated large class-wide effects, and observational reports are vulnerable to confounding. Men prescribed beta-blockers or multiple medications may already have more advanced cardiovascular disease, which independently raises erectile risk. Expectations matter as well: awareness that a medication might cause sexual dysfunction can increase symptom reporting, a phenomenon sometimes called a nocebo effect.
At the same time, population-level uncertainty should not invalidate an individual pattern. A symptom that begins soon after a new medication or dose increase, improves after a clinician-directed change, and returns on rechallenge is more suggestive of a drug contribution. The timing, baseline erectile function, other new symptoms, and concurrent medications all matter.
How Clinicians Evaluate a New Change in Erectile Function
Do not stop an antihypertensive medication abruptly. Sudden withdrawal—particularly of certain beta-blockers or centrally acting drugs—can cause rebound hypertension, rapid heart rate, chest pain, or other serious complications. A medication review with the prescribing clinician is the appropriate next step.
Evaluation usually starts with a timeline. When did the erectile change begin? Was it after a new prescription, a dose increase, or a second blood pressure drug? Is the difficulty consistent or situational? Are spontaneous or morning erections still present? Clinicians may also review alcohol use, smoking, sleep, mood, relationship factors, and drugs that can affect sexual function, including some antidepressants, opioids, and prostate medications.
Blood pressure control and cardiovascular risk should be reassessed rather than assumed. Depending on the clinical picture, testing may include fasting glucose or hemoglobin A1c, a lipid panel, kidney function, and an early-morning testosterone level when symptoms suggest androgen deficiency. Erectile dysfunction accompanied by exertional chest discomfort, marked shortness of breath, or poor exercise tolerance warrants cardiovascular evaluation before sexual activity or ED treatment.
If a medication contribution seems plausible, a clinician may consider a dose adjustment or substitution within an appropriate blood pressure regimen. For example, some men taking a non-vasodilating beta-blocker for uncomplicated hypertension may be candidates for another class, but beta-blockers remain essential in conditions such as certain arrhythmias, heart failure, or after myocardial infarction. The cardiovascular indication takes priority, and any change must be individualized.
Treatment Options and Cardiovascular Safety
Improving vascular health may support both blood pressure and erectile function. Regular aerobic activity, resistance training, smoking cessation, weight reduction when indicated, adequate sleep, and a dietary pattern rich in vegetables, legumes, whole grains, fish, and unsaturated fats may improve endothelial function. These measures are not substitutes for prescribed medication, but they address shared mechanisms.
Phosphodiesterase type 5 inhibitors, including tadalafil, sildenafil, and vardenafil, are established treatments for erectile dysfunction. They enhance nitric-oxide signaling rather than creating arousal on their own. Many men with stable, treated hypertension can use them under medical supervision, but the medication list and cardiovascular status must be reviewed first.
PDE5 inhibitors must not be combined with nitrate drugs such as nitroglycerin or isosorbide because the interaction can cause a dangerous fall in blood pressure. Caution may also be required with alpha-blockers, multiple antihypertensives, very low baseline blood pressure, significant heart disease, or medications that alter PDE5 inhibitor metabolism. “Natural” sexual-enhancement supplements are not a safer workaround; some contain undisclosed prescription ingredients and unpredictable doses.
For more evidence-based context on causes, evaluation, and treatment, the men’s sexual health library provides additional clinical guides.
Conclusion
Hypertension can impair the vascular biology required for an erection, and this underlying disease may explain part of the association commonly attributed to medication. Current evidence suggests that most major antihypertensive classes have neutral or inconsistent average effects on erectile function, while older centrally acting agents and some non-vasodilating beta-blockers deserve closer attention. A new symptom should prompt a structured review—not an abrupt decision to stop cardiovascular treatment. With clinician-guided adjustment, risk-factor management, and appropriate ED therapy, some men experience improvement while maintaining safe blood pressure control.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including Red Pill, starting with a free online assessment at questionnaire.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Zhao C, Feng JL, Deng S, et al. Genetically predicted hypertension, antihypertensive drugs, and risk of erectile dysfunction: a Mendelian randomization study. Frontiers in Cardiovascular Medicine. 2023;10:1157467. doi:10.3389/fcvm.2023.1157467
Farmakis IT, Pyrgidis N, Doundoulakis I, et al. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. Cardiovascular Drugs and Therapy. 2022;36(5):903-914. doi:10.1007/s10557-021-07197-9
Corona G, Vena W, Pizzocaro A, et al. Anti-hypertensive medications and erectile dysfunction: focus on beta-blockers. Endocrine. 2025;87(1):11-26. doi:10.1007/s12020-024-04020-x
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.